Vantas is generally used in the therapeutic domain of hormone-dependent cancer management. Its primary use is applied in addressing the symptomatic burden associated with advanced prostate cancer. This drug is indicated for the palliative treatment of hormone-dependent advanced prostate cancer. This is an area of support often used in clinical settings that involve acute or unstable symptom patterns.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms. In conditions where symptoms may intensify temporarily, Vantas is relevant for easing symptoms related to physical discomfort and symptoms that interfere with daily functioning. This approach contributes to easing the overall symptom load and may assist with maintaining a sense of stability during symptomatic periods. This treatment is applicable within clinical settings that involve acute or disruptive symptom patterns, where short-term symptomatic assistance is needed.

This supportive relief for the symptoms related to physical discomfort helps patients cope more steadily. One of the main patient-oriented benefits is that it: “provides support that helps ease the overall symptom burden”. This assists with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Relief for Symptoms related to physical discomfort

Regulatory References

1. Health Canada Summary Basis of Decision for Vantas

Eligibility Scope

• Populations for whom use is allowed: Vantas is approved for use in adult men. Use is established in the older adult population, as they comprised the majority of patients in clinical trials.
• Populations for whom use is contraindicated: Use is strictly prohibited for patients with a known hypersensitivity to GnRH, GnRH agonist analogs, or any implant component. It is also contraindicated for pediatric patients and women who are or may become pregnant (Pregnancy Category X).
• Age-related eligibility rules: Use is contraindicated in the pediatric population.
• Condition-specific eligibility rules: No change in drug dosing is warranted for patients with mild to severe renal impairment. Patients with risk factors for spinal cord compression, urinary tract obstruction, cardiovascular disease, or hyperglycemia require close monitoring during therapy.
• Pregnancy and lactation eligibility status: Contraindicated in pregnancy; use is generally not recommended for nursing mothers.

---

Eligibility Classifications (High-Level)

• Eligibility severity classification: Formal classifications include Contraindicated (Hypersensitivity, Pregnancy, Pediatric) and mandatory Close Monitoring Required (for specific comorbidity risks).
• Regulatory basis: Based on official labeling from government authorities.
• Eligibility-context constraints: Use is confined to the adult male population.

---

Resulting Eligibility Structure

Official eligibility statements:

• Vantas is strictly contraindicated in specific populations (pediatric, pregnancy) and requires close monitoring for others.
• No change in drug dosing is warranted for patients with mild to severe renal impairment.

Connection to the overall eligibility profile: The official regulatory profile strictly limits eligibility to adult men by explicit contraindications and provides criteria for conditional use in patients with pre-existing risks, such as cardiovascular disease or spinal/urinary obstruction.

Interactions with other medicines and products

This section describes the formally documented interaction patterns of Vantas (Histrelin Acetate) as established by government regulatory bodies.

Pharmacodynamic and Procedural Interactions

Official regulatory documentation notes a Pharmacodynamic (PD) Interaction Risk based on the drug's therapeutic class. Androgen deprivation therapy, which Vantas provides, may prolong the QT interval (affecting heart rhythm). Concomitant use with specific QT-prolonging medicinal products, such as Class IA (e.g., quinidine) and Class III (e.g., amiodarone, sotalol) antiarrhythmics, must be carefully evaluated.

Additionally, treatment with Vantas suppresses the pituitary-gonadal system. Consequently, the results of diagnostic tests intended to assess pituitary, gonadotropic, or gonadal functions may be affected or unreliable during or after treatment.

Pharmacokinetic Data and Constraints

No formal drug-drug interaction studies based on pharmacokinetics were conducted with Vantas. Regulatory labels explicitly state this lack of data, meaning there is no documented information on potential interactions involving metabolic enzymes (like the CYP system) or drug transporters. Similarly, formal studies examining interactions with food, alcohol, or herbal products are not documented in the prescribing information.

Population-Specific Exposure Note

Official data documents a population-specific finding concerning drug exposure. Serum histrelin concentrations are approximately 50% higher in patients with mild to severe renal impairment compared to those with normal kidney function. This constitutes a formal, documented change in drug levels within a specific patient population.

Biphasic Modulation of the GnRH Receptor

Vantas, containing Histrelin Acetate, is a synthetic molecule that targets the Gonadotropin-Releasing Hormone (GnRH) receptors on cells in the pituitary gland. Its mechanism is biphasic: it functions initially as a high-affinity agonist by stimulating these receptors. However, the continuous, non-pulsatile exposure provided by the implant rapidly leads to the desensitization and down-regulation of the receptors, thereby reducing the cell's functional response to endogenous GnRH signals.

Suppression of the HPG Axis Cascade

The prolonged loss of responsiveness in the pituitary gland causes a prolonged inhibition of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) secretion. Since LH is the required signal for gonadal steroidogenesis, the elimination of this stimulus functionally blocks the Hypothalamic-Pituitary-Gonadal (HPG) axis from above. This mechanistic cascade results directly in the profound reduction and maintenance of circulating testosterone levels at a consistent suppressive range.

️ Agonist-Related Mechanistic Limitation

A verifiable characteristic of all GnRH agonists is the transient stimulatory phase, commonly known as the "flare effect," which occurs during the first few weeks of therapy. This temporary, stimulatory event arises because the initial agonism causes a release of stored LH and FSH before the sustained process of receptor down-regulation is fully established. This limitation is inherent to the agonist mechanism.

Vantas is administered exclusively as a subcutaneous implant, a non-oral route that requires a procedure performed by a qualified healthcare professional. The drug’s usage pattern is defined by a fixed dose delivered over a sustained period. The standard regimen involves the insertion of one single implant containing 50 mg of Histrelin Acetate.

This fixed dose is designed for continuous, sustained release, establishing an administration schedule of once every 12 months for the duration of therapy. The implantation procedure specifies the inner aspect of the upper arm as the required anatomical site and mandates the use of sterile gloves and aseptic technique during the process.

A crucial component of the usage protocol is the mandatory removal of the implant after 12 months of use. Continuous treatment is maintained by replacing the spent device with a new 50 mg implant at the conclusion of this annual cycle.

Administration Scope Summary	Official Usage Rule
Route/Form	Subcutaneous Implant (50 mg)
Dosing Frequency	Annual (Once Every 12 Months)
Removal Rule	Must be removed after 12 months

Regarding specific populations, no dose adjustment is required for patients with mild to moderate renal impairment. Safety and efficacy have not been established for this indication in the pediatric population (under 18 years) or in cases of hepatic impairment.

Research evidence / Overview of Studies for Vantas

Evidence for Palliative Management of Advanced Prostate Cancer

Research was conducted to explore patterns of hormonal control in patients with advanced, hormone-dependent prostate cancer. The core clinical programs involved multi-center trials, which were structured as non-comparative studies. These trials were used in research examining the medication’s ability to achieve specific physiological endpoints. The main objective studied was a biomarker outcome: the assessment of achieving the reduction of serum Testosterone levels to a specific target known as castration levels. Studies monitored this biomarker in adult men receiving hormonal suppression therapy. The findings describe group patterns related to the recording of the target biomarker levels within the study intervals. This research provides context, but it does not determine whether an individual will respond similarly.

Research on Hormonal Control and Sustained Suppression

In the research scenarios studied, the implant was evaluated for its ability to deliver the medication continuously and explore the persistence of the hormonal change over the intended treatment period. Studies explored how Testosterone and Prostate-Specific Antigen (PSA) levels evolved over defined time intervals, typically 12 months. Research highlights patterns measured during the study period, showing Testosterone levels recorded at the target suppression level throughout the year of treatment for the majority of observed patients. These data show patterns related to sustained hormonal control. However, the evidence derived from these settings primarily monitors physiological imbalance rather than long-term clinical outcomes.

Long-Term Data and Extended Follow-up

After the initial 12-month trials were completed, some participants were observed in extended, open-label research scenarios. These studies were used in research exploring how hormonal control persisted during subsequent years of treatment, extending follow-up for up to several years. The research described in these longer-term studies, reporting that Testosterone levels were recorded at the target level in the observed populations. Research highlights changes measured during the study period regarding the persistence of the hormonal suppression. Nevertheless, there is limited information for long-term outcomes, and the number of patients followed for the longest durations was naturally reduced compared to the initial short-term study cohort.

Key Studies & References

1. Histrelin: in advanced prostate cancer (Review of Phase II and III trials)
2. ClinicalTrials.gov: Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer (NCT01697384 - Primary Endpoint: Testosterone Suppression)

Common questions about Vantas (FAQ)

---

Q: How is Vantas different from other medicines that treat the same thing?

Vantas is administered as a subcutaneous implant, which means it is placed just beneath the skin and is not taken orally or via regular injection. This implant is designed to provide continuous, sustained release of the medication for a full 12 months, which differentiates its delivery method from other medicines in the same class.

Q: Does Vantas interact with common over-the-counter pain relievers?

According to the official product information, no formal studies examining general drug-drug interactions were conducted with Vantas. This means that specific pharmacokinetic data, including information on potential interactions with common over-the-counter pain relievers, is not documented in regulatory sources.

Q: Are there any specific foods or drinks I should avoid while taking Vantas?

Regulatory documents state that formal studies examining interactions between Vantas and food, alcohol, or herbal products are not documented. Therefore, specific restrictions related to food or drink based on formal regulatory study data are not available.

Q: Can I take Vantas if I have a history of heart issues?

Official warnings note that the drug class is associated with a reported risk of serious cardiovascular events and may affect the QT interval (heart rhythm). Regulatory documents state that patients with a history of heart issues typically receive careful assessment and close monitoring during Vantas therapy.

Q: Does Vantas work immediately after taking it?

No, Vantas does not achieve its full suppressive effect immediately. Official information confirms that the medication causes a transient increase in testosterone, known as the 'flare effect,' during the first week of treatment before the sustained hormonal suppression is fully established.

Q: What does the research say about the long-term use of Vantas?

Research data describe the persistence of hormonal suppression (reaching target testosterone levels) over several years in observed patient populations. However, regulatory evidence highlights that there is limited information available concerning long-term clinical outcomes.

Q: Can Vantas cause changes in mood or sleep?

Official safety information lists mood changes and depression as commonly reported side effects. Additionally, problems getting to sleep (insomnia) have also been reported by some patients.

Q: Can Vantas be crushed or split?

Vantas is manufactured as an intact, solid subcutaneous implant that is surgically inserted beneath the skin. It is not an oral tablet and is not designed to be crushed, split, or physically altered in any way.

Q: What happens if I forget to take Vantas for a day?

Because Vantas is a single implant that releases medication continuously on an annual schedule, there is no daily dose to 'forget.' The usage protocol mandates that the existing implant must be removed after 12 months, and a new one must be inserted to continue treatment.

Q: Is it normal to feel slightly dizzy when first starting Vantas?

Dizziness is a side effect that has been reported in regulatory information. Any new or worsening symptoms, including dizziness, are generally addressed by a healthcare professional.

Q: Is Vantas safe for people with kidney problems?

Official guidelines state that no dose adjustment is required for patients with mild to moderate kidney impairment. However, official pharmacokinetic data reports that serum drug concentrations are approximately 50% higher in patients with renal impairment compared to those with normal kidney function.

Q: Is Vantas the same as another drug that has a similar name?

Vantas is one of two subcutaneous implants in the U.S. that contain the same active ingredient, histrelin acetate. The other product, Supprelin LA, is approved for use in a different population (children) and releases a slightly different daily dose of the medication.

Q: Will Vantas cause me to gain or lose weight?

Official safety information lists both weight gain and weight loss as reported side effects associated with the use of Vantas.

Q: Do I need to have regular blood tests while I am taking Vantas?

The use of blood tests is described in regulatory documents for monitoring the effectiveness of therapy and checking hormone levels. Additionally, patients are monitored for other changes, including blood glucose levels, due to the reported risk of hyperglycemia (high blood sugar) associated with the drug class.

Q: What is the risk of having an allergic reaction to Vantas?

Vantas is strictly contraindicated (prohibited) if a patient has a known allergy or hypersensitivity to the active substance, other GnRH agonists, or any component of the implant. Regulatory documents also note that the packaging for the implant may contain latex rubber, which may cause severe allergic reactions in latex-sensitive individuals.

Q: When did Vantas first become available?

Vantas was first approved by the U.S. Food and Drug Administration (FDA) on October 12, 2004, based on the review of its New Drug Application (NDA).

Q: Are there long-term side effects that are rare but serious?

Long-term use of the GnRH agonist class is associated with several reported serious risks. These include the potential for decreased bone mineral density (osteoporosis), and an increased risk of developing hyperglycemia/diabetes and major cardiovascular events (such as heart attack or stroke).

Q: Why are some people concerned about using Vantas?

Concerns generally relate to the well-documented Warnings and Precautions highlighted in the official prescribing information. These warnings cover the potential for serious adverse events associated with the drug class, such as cardiovascular events, hyperglycemia, and decreased bone mineral density during long-term therapy.

Q: Is Vantas available in different strengths?

Vantas is available in one strength as a single 50 mg subcutaneous implant.

Q: Are there any known issues with Vantas and driving?

According to official regulatory documentation, no studies specifically examining the effects of Vantas on the ability to drive and use heavy machinery have been performed.

Q: Is it true that Vantas has a Black Box Warning?

Official FDA labeling contains a Boxed Warning that highlights certain risks associated with the therapy. This warning addresses the risk of a transient increase in serum testosterone during the first week and the risk of major cardiovascular events associated with the drug class.

Q: Can I use Vantas if I have a known allergy to other similar drugs?

Vantas is contraindicated (prohibited) if a patient has a known allergy or hypersensitivity to the active substance (histrelin acetate) or to other medicines called GnRH agonists or their analogues.

Q: What should I do if I accidentally take two doses of Vantas?

Vantas is administered as a single implant on an annual schedule, and the procedure mandates that the existing implant must be surgically removed after 12 months before a new implant is inserted. This protocol ensures the necessary continuous drug release is maintained over the intended period of therapy.

Q: Is Vantas a habit-forming or controlled substance?

Based on its pharmacological properties and regulatory status, Vantas (histrelin) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA).

The official storage and disposal requirements for Vantas (histrelin implant) are defined by government regulatory documents to ensure product stability and safety.

Storage Conditions

Component	Required Temperature	Stability Constraint
Implant (Sealed Carton)	Refrigerated (2 C to 8 C)	Must not freeze; Protect from light
Implantation Kit	Controlled Room Temperature (20 C to 25 C)	Should not be refrigerated

Stored in its sealed packaging, the implant may remain at room temperature for a maximum of seven days before use. If not used within this period, the packaged implant may be returned to proper refrigeration until its expiration date.

Disposal and Handling

The Vantas implant is a non-biodegradable device that must be surgically removed after 12 months. All insertion and removal procedures require the use of sterile gloves and aseptic technique. Any unused medicine, including the implant and kit supplies, must be kept out of the sight and reach of children. Disposal of unused or expired medicine should follow pharmaceutical waste guidelines, typically through drug take-back programs or, if unavailable, household disposal rules established by the FDA and local regulations.